Breast cancer and its treatment with radiotherapy may be associated with systemic inflammatory, hematological, cardiac, body composition, functional and quality-of-life alterations. Exercise has emerged as a non-pharmacological strategy with potential benefits during oncological treatment; however, further evidence is needed regarding the effects of supervised moderate-intensity interval aerobic exercise during radiotherapy. This randomized controlled trial aims to evaluate the effects of a supervised moderate-intensity interval aerobic exercise programme on systemic inflammatory and immune-derived hematological indices, cardiac biomarkers, body composition, muscle strength, lower-limb power, sleep quality and breast cancer-specific quality of life in women with breast cancer undergoing radiotherapy. Participants will be allocated to either an experimental group performing supervised moderate-intensity interval aerobic exercise during radiotherapy or to a control group receiving usual care without structured exercise during the study period. Outcomes will be assessed at baseline and after completion of the intervention period.
Age range
20 Years – 65 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Systemic Immune-Inflammation Index (SII)
Timeframe: Baseline (pre-intervention) and immediately after intervention
Neutrophil-to-Lymphocyte Ratio (NLR)
Timeframe: Baseline (pre-intervention) and immediately after intervention
Platelet Count
Timeframe: Baseline (pre-intervention) and immediately after intervention
Neutrophil Count
Timeframe: Baseline (pre-intervention) and immediately after intervention
Lymphocyte Count
Timeframe: Baseline (pre-intervention) and immediately after intervention
NT-proBNP
Timeframe: Baseline (pre-intervention) and immediately after intervention
High-Sensitivity Troponin I
Timeframe: Baseline (pre-intervention) and immediately after intervention
Body Weight
Timeframe: Baseline (pre-intervention) and immediately after intervention
Phase angle
Timeframe: Baseline (pre-intervention) and immediately after intervention
Fat Mass
Timeframe: Baseline (pre-intervention) and immediately after intervention
Muscle Mass
Timeframe: Baseline (pre-intervention) and immediately after intervention
Percentage Body Fat
Timeframe: Baseline (pre-intervention) and immediately after intervention
Visceral fat area
Timeframe: Baseline (pre-intervention) and immediately after intervention
Relative Lower-Limb Power: Handgrip Strength
Timeframe: Baseline (pre-intervention) and immediately after intervention
Relative Lower-Limb Power (Chair Stand Test)
Timeframe: Baseline (pre-intervention) and immediately after intervention
Breast Cancer-Specific Functional Quality of Life
Timeframe: Baseline (pre-intervention) and immediately after intervention
Breast Cancer-Specific Symptom Burden
Timeframe: Baseline (pre-intervention) and immediately after intervention
Sleep Quality (PSQI)
Timeframe: Baseline (pre-intervention) and immediately after intervention